コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 portant for designing safe and selective CNS antibody therapeutics.
2 to the development of recombinant monoclonal antibody therapeutics.
3 ntages inherent to chronic administration of antibody therapeutics.
4 st commonly adopted isotype among monoclonal antibody therapeutics.
5 lls are an emerging class of next-generation antibody therapeutics.
6 information on the higher order structure of antibody therapeutics.
7 in ongoing rational design of EGFR-targeted antibody therapeutics.
8 to host cells, and is the intended target of antibody therapeutics.
10 red, offering the potential of intracellular antibody therapeutics against human immunodeficiency vir
14 he discovery and development of vaccines and antibody therapeutics, and help us gain a deeper underst
17 ble) region is a vital component of existing antibody therapeutics, as well as many next generation b
18 decade ago, the realization that monoclonal antibody therapeutics could be engineered to improve the
20 eterminants could be targeted for vaccine or antibody therapeutic development against multiple alphav
22 ad-spectrum vaccine capable of generating an antibody therapeutic effective against the multiple stra
24 luble ligands have commonly been targeted by antibody therapeutics for cancers and other diseases.
25 iding a rationale to test their potential as antibody therapeutics for diverse neurological and other
27 ering methodology for generating fully human antibody therapeutics from murine mAbs produced from sta
28 roperties will differentiate next generation antibody therapeutics from traditional IgG1 scaffolds.
29 particular challenge to targeting EGFR with antibody therapeutics has been resistance, resulting fro
30 tions such as antibody arrays and monoclonal antibody therapeutics have increased the demand for more
31 he risk of developing de novo donor-specific antibodies, therapeutic immunosuppression is the most ob
32 itial criteria for success of any protein or antibody therapeutic is to understand its binding charac
33 ecies, and the mechanism of these monoclonal antibody therapeutics is still not understood in detail.
36 major problem in an industrial setting where antibody therapeutics often require high local concentra
37 the exploration of promising glycoforms for antibody therapeutics.Post-translational modifications c
38 critical quality attribute for a monoclonal antibody therapeutic product due to its perceived signif
39 ed glycan profiles on recombinant monoclonal antibody therapeutics significantly affect antibody biol
40 lds offer low-cost alternatives to classical antibody therapeutic strategies and some have shown earl
43 his review will discuss the pros and cons of antibody therapeutics targeted at bacterial infections.
44 bloodstream infection; however, vaccines and antibody therapeutics targeting staphylococcal surface m
45 marked synergy of EAI045 with cetuximab, an antibody therapeutic that blocks EGFR dimerization, rend
46 ryptococcal meningitis and for the design of antibody therapeutics to treat other infectious diseases
47 n models revealed windows of opportunity for antibody therapeutic treatment that correlated well with
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。